Variables | Overall survival | Disease-free survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age(y) | ||||||
≤ 55 | 1 | 1 | ||||
> 55 | 0.987 | 0.629–1.548 | 0.954 | 0.703 | 0.383–1.289 | 0.254 |
Sex | ||||||
Female | 1 | 1 | ||||
Male | 2.275 | 1.135–4.559 | 0.021 | 2.089 | 0.820–5.320 | 0.122 |
Surgical approach | ||||||
Open surgery | 1 | 1 | ||||
MIE | 0.557 | 0.358–0.867 | 0.010 | 0.618 | 0.337–1.134 | 0.120 |
Operation date | ||||||
2010.1–2013.12 | 1 | 1 | ||||
2014.1–2016.12 | 0.891 | 0.587–1.352 | 0.588 | 0.954 | 0.513–1.771 | 0.880 |
Location | ||||||
Upper third | 1 | 1 | ||||
Middle third | 0.972 | 0.581–1.608 | 0.915 | 2.083 | 1.007–4.307 | 0.048 |
Lower third | 1.134 | 0.632–2.032 | 0.674 | 0.726 | 0.248–2.124 | 0.558 |
Pathological T stage | ||||||
0 | 1 | 1 | ||||
T1 | 2.367 | 1.181–4.743 | 0.015 | 1.219 | 0.354–4.202 | 0.754 |
T2 | 1.401 | 0.742–2.646 | 0.298 | 1.999 | 0.907–4.410 | 0.086 |
T3 | 2.531 | 1.559–4.110 | < 0.001 | 1.584 | 0.760–3.303 | 0.220 |
Pathological N stage | ||||||
N0 | 1 | 1 | ||||
N1 | 1.347 | 0.806–2.250 | 0.255 | 1.207 | 0.582–2.505 | 0.613 |
N2 | 3.673 | 2.077–6.496 | < 0.001 | 1.651 | 0.574–4.751 | 0.353 |
N3 | 4.051 | 1.822–9.008 | 0.001 | 2.060 | 0.487–8.710 | 0.326 |
Grade | ||||||
Posttreatment change | 1 | 1 | ||||
G1 | 1.738 | 0.763–3.958 | 0.188 | 0.889 | 0.205–3.850 | 0.875 |
G2 | 1.800 | 1.078–3.007 | 0.025 | 1.181 | 0.552–2.526 | 0.668 |
G3 | 2.473 | 1.457–4.196 | 0.001 | 2.038 | 0.970–4.281 | 0.060 |
ypTNM stage | ||||||
I | 1 | 1 | ||||
II | 1.431 | 0.699–2.930 | 0.327 | 1.618 | 0.680–3.851 | 0.277 |
III | 2.238 | 1.369–3.660 | 0.001 | 1.457 | 0.130–2.910 | 0.286 |
IV | 3.906 | 1.505–10.135 | 0.005 | 2.296 | 0.533–9.893 | 0.266 |
Neoadjuvant therapy | ||||||
Chemotherapy | 1 | 1 | ||||
Chemoradiation | 0.732 | 0.470–1.141 | 0.168 | 1.160 | 0.617–2.182 | 0.645 |
Postoperative therapy | ||||||
No | 1 | 1 | ||||
Yes | 0.503 | 0.319–0.794 | 0.003 | 0.111 | 0.056–0.218 | < 0.001 |